Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
RBA Expected to Hold Interest Rates at 4.35% as Markets Watch AUD/USD and ASX 200 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
SoftBank Vision Fund CFO Navneet Govil to Exit After Decade-Long Tenure 
US Stock Futures Edge Higher Ahead of Key Federal Reserve Decision 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
BOJ Raises Interest Rates to 31-Year High, Signals Strong Focus on Inflation Risks 
SpaceX Stock Gets $175 Target as Analysts See Massive Growth Ahead 
AI-Focused Asia Hedge Funds Deliver Triple-Digit Returns in 2026 Rally 
Asian Currencies Steady as Dollar Holds Firm Ahead of Fed Decision and US-Iran Deal Details 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Dollar Slips as U.S.-Iran Peace Deal Boosts Risk Appetite and Pressures Safe-Haven Demand 
Sigma Healthcare Shares Jump After Exiting Boots Acquisition Process 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
